AbbVie Inc. exhibits a robust dividend profile, presenting a commendable yield and an established history of consistent payments. Despite high payout ratios, the company's stable dividend growth and solid financial fundamentals support a positive outlook. Investors should weigh the high debt levels against the strategic growth prospects.
📊 Overview
This section provides a snapshot of AbbVie's dividend metrics, which serve as critical indicators of its attractiveness to income-focused investors.
Metric
Value
Sector
Healthcare
Dividend yield
3.0221 %
Current dividend per share
6.23 USD
Dividend history
14 years
Last cut or suspension
None
📈 Dividend History
AbbVie's dividend history highlights its commitment to returning capital to shareholders. Consistency in dividend payments enhances investor confidence and aligns with long-term financial strategies.
AbbVie's Historical Dividend Payments
Year
Dividend per Share (USD)
2026
1.73
2025
6.56
2024
6.20
2023
5.92
2022
5.64
📊 Dividend Growth
Dividend growth is crucial for gauging sustainability and potential future increases. It reflects management's confidence in cash flow generation and profitability.
Time
Growth
3 years
5.17 %
5 years
6.81 %
The average dividend growth rate is 6.81 % over 5 years, indicating moderate but steady improvement.
AbbVie's Dividend Growth Analysis
⚠️ Payout Ratio
Payout ratios measure the proportion of earnings and cash flows paid out as dividends, critical for assessing dividend sustainability and coverage.
Key figure
Ratio
EPS-based
461.31 %
Free cash flow-based
53.55 %
The EPS-based payout is unsustainably high, signaling potential risk, while the FCF-based payout remains at an acceptable level, suggesting manageable dividend coverage.
💼 Cashflow & Capital Efficiency
Understanding cash flow dynamics and capital efficiency is pivotal in evaluating a company's ability to sustain and grow dividends.
Metric
2024
2023
2022
Free Cash Flow Yield
5.67%
8.05%
8.47%
Earnings Yield
1.36%
1.77%
4.14%
CAPEX to Operating Cash Flow
1.40%
3.40%
2.79%
Stock-based Compensation to Revenue
2.46%
1.38%
1.16%
Free Cash Flow / Operating Cash Flow
94.82%
96.60%
97.21%
Return on Invested Capital
12.96%
9.56%
14.02%
The strong free cash flow yield alongside high capital returns indicates proficient cash generation and potent capital deployment, pivotal for supporting dividend continuity.
🏦 Balance Sheet & Leverage Analysis
Balance sheet strength and leverage analysis reflect financial stability, capacity for future debt repayments, and overall risk profile.
Metric
2024
2023
2022
Debt-to-Equity
20.40
5.80
3.72
Debt-to-Assets
50.19%
44.63%
46.25%
Debt-to-Capital
95.33%
85.30%
78.82%
Net Debt to EBITDA
4.96
2.75
2.27
Current Ratio
0.72
0.87
0.96
Quick Ratio
0.55
0.76
0.84
Financial Leverage
40.65
13.00
8.04
While leverage is notably high, indicating substantial use of debt, the company's ability to cover interest obligations remains sufficiently stable and warrants close monitoring.
🔎 Fundamental Strength & Profitability
Analyzing profitability metrics provides valuable insights into the operational efficiency and financial health of the enterprise.
Metric
2024
2023
2022
Return on Equity
128.66%
46.94%
68.60%
Return on Assets
3.17%
3.61%
8.53%
Net Margin
7.59%
8.95%
20.39%
EBIT Margin
11.58%
15.60%
27.06%
EBITDA Margin
26.47%
31.61%
41.64%
Gross Margin
69.99%
62.42%
70.00%
R&D to Revenue
22.11%
14.13%
11.21%
While return metrics fluctuate, they suggest strong profitability and efficient operations, underpinned by high gross margins and significant reinvestments in R&D.
📈 Price Development
AbbVie's Stock Price Trend
🏅 Dividend Scoring System
Category
Score
Bar
Dividend yield
4
Dividend Stability
3
Dividend growth
4
Payout ratio
2
Financial stability
3
Dividend continuity
5
Cashflow Coverage
4
Balance Sheet Quality
3
Total Score: 28/40
✅ Rating
Based on AbbVie's extensive dividend profile, continuous dividend payments, and robust cash flow generation, the stock holds a favorable outlook. While the elevated payout ratios and leverage require vigilance, the solid dividend growth and financial performance support a positive, albeit cautious, recommendation for dividend-seeking investors.
